Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
about
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis.
P2860
Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Safety and efficacy of high-do ...... dosis and cardiac involvement.
@en
Safety and efficacy of high-do ...... dosis and cardiac involvement.
@nl
type
label
Safety and efficacy of high-do ...... dosis and cardiac involvement.
@en
Safety and efficacy of high-do ...... dosis and cardiac involvement.
@nl
prefLabel
Safety and efficacy of high-do ...... dosis and cardiac involvement.
@en
Safety and efficacy of high-do ...... dosis and cardiac involvement.
@nl
P2093
P2860
P356
P1476
Safety and efficacy of high-do ...... idosis and cardiac involvement
@en
P2093
D C Seldin
H K Meier-Ewert
V Sanchorawala
P2860
P2888
P304
P356
10.1038/BMT.2013.192
P407
P577
2013-12-09T00:00:00Z